Half-life extension using serum albumin-binding DARPin® domains

Half-life extended biotherapeutics

(2016) Roland E. Kontermann   EXPERT OPINION ON BIOLOGICAL THERAPY

Effects of the linker region on the structure and function of modular GH5 cellulases

(2016) Diego M. Ruiz et al.   Scientific Reports

Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy

(2015) Andreas Plückthun   Annual Review of Pharmacology and Toxicology

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

(2015) William R. Strohl   BIODRUGS

Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension

(2015) Laura J. Goodall et al.   PLoS One

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety

(2014) R L O’Connor-Semmes et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Protein HESylation for half-life extension: Synthesis, characterization and pharmacokinetics of HESylated anakinra

(2014) Robert Liebner et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Albumin and its application in drug delivery

(2014) Darrell Sleep   Expert Opinion on Drug Delivery

Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein

(2013) A. Orlova et al.   JOURNAL OF NUCLEAR MEDICINE

Renal albumin filtration: alternative models to the standard physical barriers

(2013) Marcus J. Moeller et al.   Nature Reviews Nephrology

Fusion protein linkers: Property, design and functionality

(2012) Xiaoying Chen et al.   ADVANCED DRUG DELIVERY REVIEWS

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

(2012) Mischa R. Müller et al.   mAbs

Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size

(2010) C. Zahnd et al.   CANCER RESEARCH

Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon

(2010) A. Walker et al.   PROTEIN ENGINEERING DESIGN & SELECTION

The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein

(2010) J. Hopp et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

(2009) Jie Ling et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

(2009) Volker Schellenberger et al.   NATURE BIOTECHNOLOGY

DARPins: A new generation of protein therapeutics

(2008) Michael T. Stumpp et al.   DRUG DISCOVERY TODAY

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

(2008) L. J. Holt et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Engineering of a femtomolar affinity binding protein to human serum albumin

(2008) A. Jonsson et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Folding and Unfolding Mechanism of Highly Stable Full-Consensus Ankyrin Repeat Proteins

(2007) Svava K. Wetzel et al.   JOURNAL OF MOLECULAR BIOLOGY

Characterization and Further Stabilization of Designed Ankyrin Repeat Proteins by Combining Molecular Dynamics Simulations and Experiments

(2007) Gianluca Interlandi et al.   JOURNAL OF MOLECULAR BIOLOGY